Form 4: Avidity Biosciences Director Sells Shares for Tax Obligations

Avidity Biosciences director Arthur A. Levin sold 1,758 shares of common stock in a non-discretionary transaction to cover tax withholding obligations.

Summary

• Arthur A. Levin, a Director at Avidity Biosciences, Inc. (RNA), reported a sale of common stock.
• On January 21, 2026, 1,758 shares of common stock were sold at a price of $72.45 per share.
• The transaction was a "sell-to-cover" to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) on January 20, 2026.
• This sale was mandated by the Issuer's equity incentive plans and was not a discretionary trade by Mr. Levin.
• The transaction was executed pursuant to a Rule 10b5-1 plan.
• Following the transaction, Mr. Levin directly owns 16,562 shares and indirectly owns 131,372 shares via a family trust and 22,500 shares via a charitable remainder trust.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax purposes, which is a neutral event and does not indicate positive or negative sentiment towards the company's prospects.

Positives

• The sale was non-discretionary, indicating it was not a signal of lack of confidence in the company by the director.
• The transaction was pre-planned under a Rule 10b5-1 plan, demonstrating adherence to insider trading regulations.

Negatives

• No specific negatives are identified as the sale was non-discretionary and for tax purposes.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell-to-cover' transaction and does not represent a discretionary trade by the Reporting Person.
• The Reporting Person has executed an instruction letter for the automatic sale of such 'sell-to-cover' shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.

Industry Context

This routine insider transaction, a non-discretionary 'sell-to-cover' for tax purposes, is common practice across all industries, particularly in biotechnology where executive compensation often includes equity awards. It does not reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• Sell-to-cover transactions are standard practice for executives and directors across publicly traded companies, including peers in the biotechnology sector such as Moderna (MRNA) or BioNTech (BNTX), when Restricted Stock Units (RSUs) vest and trigger tax obligations.
• The use of a Rule 10b5-1 plan for such transactions is also a common and recommended corporate governance practice to avoid accusations of insider trading, aligning with best practices seen at companies like Pfizer (PFE) or Johnson & Johnson (JNJ).

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and not a signal of management's view on the company's future.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• No specific future actions or milestones are mentioned beyond the completion of the reported transaction.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by a director to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or the director's confidence. Therefore, it provides no new information that would warrant a change in an existing investment thesis, leading to a 'hold' recommendation.

Keywords

Avidity Biosciences, RNA, Arthur A. Levin, Form 4, Insider Trading, Stock Sale, Sell-to-Cover, RSU Vesting, Tax Withholding, Rule 10b5-1